Centre for Commercialization of Cancer Immunotherapy

The Centre for Commercialization of Cancer Immunotherapy (C3i) operates as a specialized Contract Development and Manufacturing Organization for complex cell and gene therapies. It offers comprehensive services across development, translation, and manufacturing of advanced cellular treatments, focused on oncology. C3i's core capability efficiently moves innovative therapeutic modalities from research to clinical application, accelerating commercial readiness.

Established in 2016, C3i was founded as a non-profit under the Canadian government’s Centres of Excellence in Commercialization and Research (CECR) program. This strategic initiative, backed by Canadian and Quebec government investments, addressed the critical need for expertise in commercializing sophisticated cancer immunotherapies. Its core insight was to bridge scientific discovery and patient access for these complex treatments.

C3i serves academic researchers, biotechnology companies, and pharmaceutical firms requiring specialized cell and gene therapy manufacturing and development expertise. Its vision is to accelerate the availability of innovative cancer immunotherapies. By providing essential infrastructure and support, C3i enhances the accessibility and impact of advanced cellular treatments, fostering future progress in cancer care.